Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription


2 Ann Surg Oncol
3 Ann Thorac Surg
4 BMC Cancer
7 Clin Cancer Res
3 Clin Lung Cancer
1 J Surg Oncol
4 J Thorac Cardiovasc Surg
4 Lancet Oncol
3 Lung Cancer
1 Oncol Rep
3 Thorax

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Surg Oncol

    Segmentectomy...Because We Can or Because We Should?
    Ann Surg Oncol. 2022;29:28-29.

  2. DAI W, Mu Y, Chang S, Wu Z, et al
    ASO Author Reflections: Using Patient-Reported Outcomes to Compare Thoracoscopic Segmentectomy and Lobectomy.
    Ann Surg Oncol. 2022;29:557-558.

    Ann Thorac Surg

  3. REISENAUER J, Simoff MJ, Pritchett MA, Ost DE, et al
    Ion: Technology and Techniques for Shape-sensing Robotic-assisted Bronchoscopy.
    Ann Thorac Surg. 2022;113:308-315.
    PubMed         Abstract available

  4. ZHOU N, Rice DC, Tsao AS, Lee PP, et al
    Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma.
    Ann Thorac Surg. 2022;113:200-208.
    PubMed         Abstract available

  5. MANGANA O, Perrot L, Foussier C, Salvi S, et al
    Incomplete Carney Triad: A Surgical Case of a Rare Syndrome.
    Ann Thorac Surg. 2022;113:e53-e55.
    PubMed         Abstract available

    BMC Cancer

  6. TUBIO-PEREZ RA, Torres-Duran M, Garcia-Rodriguez ME, Candal-Pedreira C, et al
    Alpha-1 antitrypsin deficiency and risk of lung cancer in never-smokers: a multicentre case-control study.
    BMC Cancer. 2022;22:81.
    PubMed         Abstract available

  7. TUMINELLO S, Alpert N, Veluswamy RR, Kumar A, et al
    Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis.
    BMC Cancer. 2022;22:80.
    PubMed         Abstract available

  8. ZHOU Y, Yu T, Zhang Y, Qian L, et al
    Comparison of surgical outcomes and prognosis between wedge resection and simple Segmentectomy for GGO diameter between 2 cm and 3 cm in non-small cell lung cancer: a multicenter and propensity score matching analysis.
    BMC Cancer. 2022;22:71.
    PubMed         Abstract available

  9. SHARP J, Prasad V
    An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).
    BMC Cancer. 2022;22:70.
    PubMed         Abstract available

    Clin Cancer Res

  10. DAEMEN A, Cooper JE, Myrta S, Wongchenko MJ, et al
    Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma.
    Clin Cancer Res. 2021;27:1162-1173.
    PubMed         Abstract available

  11. GUO R, Offin M, Brannon AR, Chang J, et al
    MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance.
    Clin Cancer Res. 2021;27:799-806.
    PubMed         Abstract available

  12. AI X, Cui J, Zhang J, Chen R, et al
    Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641).
    Clin Cancer Res. 2021;27:704-712.
    PubMed         Abstract available

  13. TAN Y, Sementino E, Cheung M, Peri S, et al
    Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.
    Clin Cancer Res. 2021;27:1200-1213.
    PubMed         Abstract available

  14. HELLMANN MD, Janne PA, Opyrchal M, Hafez N, et al
    Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
    Clin Cancer Res. 2021;27:1019-1028.
    PubMed         Abstract available

  15. SUZUKI S, Yonesaka K, Teramura T, Takehara T, et al
    Correction: KRAS Inhibitor Resistance in MET-Amplified KRAS (G12C) Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
    Clin Cancer Res. 2022;28:428.

  16. TULLY KM, Tendler S, Carter LM, Sharma SK, et al
    Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer exhibits antitumor efficacy with low toxicity.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-1533.
    PubMed         Abstract available

    Clin Lung Cancer

  17. HIJMERING-KAPPELLE LBM, Hiltermann TJN, Bensch F
    Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
    Clin Lung Cancer. 2021 Dec 24. pii: S1525-7304(21)00305.
    PubMed         Abstract available

  18. LOGTENBERG ME, Tomlow B, Kastelijn EA, Schramel FMNH, et al
    Benefit of Concurrent Versus Sequential Chemoradiotherapy in Elderly Patients With Stage III Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 17. pii: S1525-7304(21)00291.
    PubMed         Abstract available

  19. ZHANG L, Yang X, Ming Z, Shi J, et al
    Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 24. pii: S1525-7304(21)00304.
    PubMed         Abstract available

    J Surg Oncol

  20. KE L, Cui S, Yang M, Chen J, et al
    Validation of a modified Caprini risk assessment model in lung cancer patients undergoing surgery: Results of a multicenter cross-sectional observational study.
    J Surg Oncol. 2022 Jan 18. doi: 10.1002/jso.26794.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  21. ZHANG Y, Chen H
    Commentary: Is sublobar resection enough for ground-glass opacity-dominant lung adenocarcinoma?
    J Thorac Cardiovasc Surg. 2022;163:303-304.

  22. DAVID EA
    Commentary: STAS is here to STAY.
    J Thorac Cardiovasc Surg. 2022;163:287-288.

  23. LIN J
    Commentary: Should we start spreading the news? Prognostic influence of spread through air spaces in early-stage lung adenocarcinoma.
    J Thorac Cardiovasc Surg. 2022;163:286-287.

    Commentary: Spread the news: Spread through air spaces matters.
    J Thorac Cardiovasc Surg. 2022;163:285.

    Lancet Oncol

  25. ZHOU Q, Chen M, Jiang O, Pan Y, et al
    Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phas
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00630.
    PubMed         Abstract available

  26. ROSELL R, Cao P
    Promising outlook with sugemalimab in non-small-cell lung cancer.
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00698.

  27. ZHOU C, Wang Z, Sun Y, Cao L, et al
    Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
    Lancet Oncol. 2022 Jan 14. pii: S1470-2045(21)00650.
    PubMed         Abstract available

  28. SCHOENFELD JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, et al
    Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
    Lancet Oncol. 2022 Jan 13. pii: S1470-2045(21)00658.
    PubMed         Abstract available

    Lung Cancer

  29. COLEMAN N, Harbery A, Heuss S, Vivanco I, et al
    Targeting un-MET needs in advanced non-small cell lung cancer.
    Lung Cancer. 2021;164:56-68.
    PubMed         Abstract available

  30. DEBOEVER N, McGrail DJ, Lee Y, Tran HT, et al
    Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.
    Lung Cancer. 2022;164:69-75.
    PubMed         Abstract available

  31. HE LN, Chen T, Fu S, Chen C, et al
    Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.
    Lung Cancer. 2021;165:10-17.
    PubMed         Abstract available

    Oncol Rep

  32. CHEN N, Zhou YS, Wang LC, Huang JB, et al
    Advances in metforminbased metabolic therapy for nonsmall cell lung cancer (Review).
    Oncol Rep. 2022;47.
    PubMed         Abstract available


  33. PERLEPE G, Kotsiou OS, Karetsi E, Papadopoulos D, et al
    Persistent consolidation: a MALT-easer.
    Thorax. 2021;76:1057-1059.

  34. SHAMSEDDIN M, Obacz J, Garnett MJ, Rintoul RC, et al
    Use of preclinical models for malignant pleural mesothelioma.
    Thorax. 2021;76:1154-1162.
    PubMed         Abstract available

  35. BARNES-HARRIS M, Allingham S, Morgan D, Ferreira D, et al
    Comparing functional decline and distress from symptoms in people with thoracic life-limiting illnesses: lung cancers and non-malignant end-stage respiratory diseases.
    Thorax. 2021;76:989-995.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.